Ultragenyx CFO sells 4,683 company shares
Ultragenyx Pharmaceutical Inc.’s Chief Financial Officer, Howard Horn, sold 4,683 shares of common stock in an open-market transaction.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical Inc.’s Chief Financial Officer, Howard Horn, sold 4,683 shares of common stock in an open-market transaction. The shares were sold at $20.97 each. After this sale, he directly holds 80,351 shares, which include previously reported RSU-based shares that vest over time.
Insider Trade Summary 10b5-1
Net Seller: 4,683 shares
Net Sell
1 txn
Insider
Horn Howard
Role
Chief Financial Officer
Sold
4,683 shs ($98K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 4,683 | $20.97 | $98K |
Holdings After Transaction:
Common Stock — 80,351 shares (Direct)
Footnotes (1)
- F1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Key Figures
Shares sold: 4,683 shares
Sale price per share: $20.97 per share
Shares held after transaction: 80,351 shares
3 metrics
Shares sold
4,683 shares
Open-market sale of common stock
Sale price per share
$20.97 per share
Open-market sale by CFO
Shares held after transaction
80,351 shares
Direct holdings after sale, including RSU-based shares
Key Terms
open-market sale, restricted stock units, beneficial ownership
3 terms
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
restricted stock units financial
"shares of common stock underlying RSUs granted to the Reporting Person"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
beneficial ownership financial
"previously reported shares of common stock underlying RSUs granted to the Reporting Person"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Ultragenyx (RARE) report for its CFO?
Ultragenyx reported that Chief Financial Officer Howard Horn sold 4,683 shares of common stock in an open-market transaction. The sale was reported on a Form 4 insider filing and reflects a routine disposition of a portion of his holdings.
What does the Form 4 footnote say about Ultragenyx (RARE) CFO’s RSUs?
The footnote explains that the reported holdings include shares underlying restricted stock units granted to Howard Horn. These RSUs are subject to specified vesting conditions, meaning the underlying shares are delivered over time as those vesting requirements are satisfied.
Was the Ultragenyx (RARE) CFO’s transaction a purchase or a sale?
The transaction reported for Ultragenyx’s Chief Financial Officer was a sale. The Form 4 identifies it with transaction code “S” and describes it as an open-market sale of 4,683 shares of common stock at a stated per-share price.
Does the Ultragenyx (RARE) Form 4 show any option exercises or derivative trades?
No derivative transactions are shown in this Form 4 excerpt. The filing’s derivative transaction summary is empty, and the single reported transaction is a non-derivative open-market sale of common stock, rather than an option exercise or other derivative-related activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
